Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK-9 Inhibitors and Vascular Inflammation
NCT02941016Phase 4Withdrawn
- Sponsor
- Rigshospitalet
- Start
- Oct 2016
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of evolocumab and alirocumab in hypercholesterolemia, sponsored by Rigshospitalet. Primary endpoint: Change in vascular inflammation at 12 weeks. Planned start Oct 2016; status: withdrawn.
02
Drugs
evolocumabalirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02941016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02941016.